Cross talk of serum elements, cardiac and liver enzymes in patients with HCV chronic hepatitis and hepatocellular carcinoma in Pakistani population

2021 ◽  
Vol 5 (1) ◽  
pp. 16-24
Author(s):  
Tabassum Naeem ◽  
Tahir Ali ◽  
Iram Mushtaq ◽  
Ayesha Ishtiaq ◽  
Iram Murtaza
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Liver Enzymes ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Individuals ◽  
Cardiac Enzymes ◽  
Pakistani Population ◽  
Liver Disorders ◽  
Normal Individuals ◽  
Kinase Ck2

HCV-associated hepatic pathologies are now the frequent inducer of cardiac abnormalities because of cardio-hepatic interaction. Studies are going on to elucidate and highlight the possible factors involved in this complex interaction, but this paradigm is still unclear. Here, we aimed to explore the interrelationship among electrolytes, cardiac, and liver enzymes in HCV-associated hepatic abnormalities, including chronic hepatitis and hepatocellular carcinoma in the Pakistani population. 100 Hepatitis C virus (HCV) infected patients with liver disorders and 50 healthy individuals were recruited in the present analysis. Trace elements, ions, and enzyme concentrations were quantified via an automatic analyzer, while HCV was confirmed by enzyme-linked immunosorbent assay (ELISA). Our results demonstrated that serum Ca++, Mg++, Fe++, Cl-, and PO4- levels were significantly increased in HCV patients with hepatic pathologies, including cirrhosis and carcinoma. Cardiac enzymes, including aspartate aminotransferase (AST), creatine kinase (CK2), and lactate dehydrogenase (LDH) concentration, were also elevated in HCV patients. Furthermore, serum cholesterol and triglyceride levels significantly differed in HCV patients than in normal individuals. Impaired alkaline transaminase (ALT) and alkaline phosphatase levels in HCV patients further validate the HCV patients' hepatic pathologies. Interestingly, all these impaired factors were positively correlated with the progression of hepatic disorders. In conclusion, altered ionic concentrations, cardiac enzymes, and liver dysfunction markers suggest their significant relationship to HCV leading liver pathologies in the Pakistani population.

Anticancer Effects of Tacrolimus on Induced Hepatocellular Carcinoma in Mice

2021 ◽  
Vol 14 ◽  
Author(s):  
Shireen Sami Mahmoud ◽  
Samia Hussein ◽  
Hayam Rashed ◽  
Eman M. A. Abdelghany ◽  
Alaa I. Ali
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cyclin D1 ◽  
Liver Enzymes ◽  
Combined Treatment ◽  
Treated Group ◽  
Nuclear Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Gamma Glutamyl Transferase ◽  
Anticancer Effects ◽  
Glutamyl Transferase

Background: Tacrolimus is a calcineurin inhibitor widely used for immunological disorders. However, there is a significant controversy regarding its effect on the liver. The present study was conducted to evaluate the anticancer effects of tacrolimus on an induced murine hepatocellular carcinoma (HCC) model and its possible hepatotoxicity at standard therapeutic doses. Methods: Fifty-four male mice were divided into five groups: a control healthy group, control HCC group, tacrolimus-treated group, doxorubicin (DOXO)-treated group, and combined tacrolimus- and DOXO-treated group. The activity of liver enzymes, including alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase, alanine transaminase, and aspartate transaminase, was determined. Serum vascular endothelial growth factor (VEGF) was measured using an enzyme-linked immunosorbent assay. A quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to measure the expression of proliferating cell nuclear antigen (PCNA), Bax, and p53 mRNA. Immunohistochemical staining for cyclin D1 and VEGF was performed. Results: Mice that received combined treatment with tacrolimus and DOXO exhibited the best improvement in all parameters when compared with the groups that received DOXO or tacrolimus alone (p < 0.001). Conclusion: The combination of DOXO and tacrolimus was more effective in the management of HCC compared with either agent alone. This improvement was detected by the reduction of liver enzymes and the improvement of the histopathological picture. The involved mechanisms included significant apoptosis induction demonstrated by upregulation of bax along with a reduction in angiogenesis demonstrated by downregulation of VEGF. This was accompanied by inhibition of cell cycle progression mediated by upregulated p53 and downregulated PCNA and cyclin D1.

scholarly journals Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Qi Zhao ◽  
Yiqiu Xu ◽  
Dandan Yuan ◽  
Junjun Yang ◽  
Ying Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Exploratory Study ◽  
Magnetic Beads ◽  
Area Under The Curve ◽  
Radical Resection ◽  
Diagnostic Value ◽  
Healthy Individuals ◽  
Diagnosis And Prognosis ◽  
Imaging Results

Background and Aim. This exploratory study explored single-stranded DNA (ssDNA) for hepatocellular carcinoma (HCC) diagnosis and prognosis. Methods. This prospective study enrolled 102 patients with newly diagnosed HCC, 21 with cirrhosis, 20 with chronic hepatitis, 284 with nonliver diseases, and 45 healthy individuals at the Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University (May-October 2018). ssDNA was extracted using magnetic beads and quantified using the Qubit ssDNA assay. ssDNA levels were compared among the disease groups and in HCC vs. non-HCC. Receiver operating characteristic (ROC) curves were used to determine the diagnostic value of ssDNA. In patients with resectable HCC, ssDNA and α-fetoprotein (AFP) levels were measured during follow-up and compared with HCC recurrence detected by imaging. Results. The median ssDNA levels were higher in HCC than in healthy individuals, cirrhosis, and chronic hepatitis (median, 23.20 vs. 9.36, 9.64, and 9.76 ng/μL, respectively, P < 0.001 ). ssDNA levels in HCC were higher than those in cirrhosis and chronic hepatitis (both P < 0.001 ); there were no differences in ssDNA levels between healthy controls and patients with cirrhosis ( P = 0.15 ) or chronic liver disease ( P = 0.39 ). The area under the curve of ssDNA for HCC diagnosis was 0.909 (95% CI: 0.879-0.933). The ssDNA levels decreased by 3.19-fold ( P < 0.001 ) after HCC radical resection. In six patients, the ssDNA levels increased about 3-6 months before a recurrence was detected by AFP and imaging. Conclusions. ssDNA might be a noninvasive indicator for HCC diagnosis and prognosis. ssDNA could eventually be complementary to AFP levels and imaging, but confirmatory studies are necessary.

scholarly journals Anti-Hepatitis B Virus X Protein in Sera Is One of the Markers of Development of Liver Cirrhosis and Liver Cancer Mediated by HBV

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
Hang Zhang ◽  
Lian-Ying Wu ◽  
Shuai Zhang ◽  
Li-Yan Qiu ◽  
Nan Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Enzyme Linked Immunosorbent Assay ◽  
X Protein ◽  
Hbv Replication ◽  
B Virus ◽  
Circulating Antibody

Hepatitis B virus X protein (HBx) plays a crucial role in the development of hepatocellular carcinoma (HCC). However, the significance of circulating antibody to hepatitis B virus X antigen (anti-HBx) in sera remains unclear. In the present study, we examined the titers of anti-HBx (IgG) in the sera from 173 patients with chronic hepatitis B (CHB), 106 liver cirrhosis (LC), and 61 HCC by enzyme-linked immunosorbent assay (ELISA), respectively. Our data showed that the positive rates of anti-HBx were higher in sera of LC (40.6%) and HCC (34.4%) than those of CHB (10.4%),P<.05. In all 40 patients with anti-HBx+ out of 340 patients, 39 (97.5%) were HBsAg/HBeAg/anti-HBc+ and 1 (2.5%) was anti-HBs+ (P<.01), suggesting that anti-HBx in sera is a marker of HBV replication rather than a protective antibody. Thus, our findings reveal that circulating anti-HBx in sera is one of the markers of development of LC and HCC mediated by HBV.

p53 and rb promoter methylation in hepatitis C virus-related chronic hepatitis and hepatocellular carcinoma

2021 ◽  
Author(s):  
Ayma Aftab ◽  
Samia Afzal ◽  
Muhammad Idrees ◽  
Ahmad Ali Shahid
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Healthy Individuals ◽  
P53 Expression ◽  
Blood Samples ◽  
Specific Pcr ◽  
Liver Biopsies ◽  
Chronic Hepatitis C Patients

Aim: To identify methylation in p53 and rb during hepatitis C virus (HCV) infection in individuals in Pakistan. Materials & methods: Methylation-specific PCR was used on liver biopsies from hepatocellular carcinoma and chronic hepatitis C patients and on blood samples from healthy individuals. Real-time PCR was used to assess changes in the expression of p53 and rb in Huh-7 cells transfected with HCV-3a. Results: The p53 and rb promoters were methylated in hepatocellular carcinoma patients. The presence of HCV-3a- Core (p = 0.03), HCV-3a- NS-3 (p = 0.01) and HCV-3a- NS-5a (p = 0.02) downregulated p53 expression. Exposure to HCV-3a- Core (p = 0.04) downregulated rb expression. Conclusion: It can be hypothesized that HCV-induced epigenetic modifications may lead to the development of hepatic cancer that in turn inactivates p53 and rb.

scholarly journals Pharmacological Effects of Ginseng on Liver Functions and Diseases: A Minireview

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Nguyen Huu Tung ◽  
Takuhiro Uto ◽  
Osamu Morinaga ◽  
Young Ho Kim ◽  
Yukihiro Shoyama
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Liver Diseases ◽  
Treatment Options ◽  
Pharmacological Effects ◽  
Liver Disorders ◽  
Beneficial Role ◽  
Liver Functions

Ginseng, an ancient and famous medicinal herb in the Orient, has been used as a valuable tonic and for the treatment of various diseases including hepatic disorders. Ginseng saponins, commonly known as ginsenosides, are principal constituents and have believed to be responsible for multiple ginseng health benefits. There are more 40 ginsenosides isolated from ginseng. To date, treatment options for common liver diseases such as cirrhosis, fatty liver, and chronic hepatitis remain problematic. In this regard, ginseng extracts and individual ginsenosides have shown a wide array of beneficial role in the regulation of regular liver functions and the treatment of liver disorders of acute/chronic hepatotoxicity, hepatitis, hepatic fibrosis/cirrhosis, hepatocellular carcinoma, and so on in various pathways and mechanisms. In this paper, we first outline the pharmacological effects of ginseng and ginsenosides on the liver functions.

Assessment of miR-212 and Other Biomarkers in the Diagnosis and Treatment of HBV-infection-related Liver Diseases

2019 ◽  
Vol 20 (10) ◽  
pp. 785-798 ◽  
Author(s):  
Yigan Zhang ◽  
Huaze Xi ◽  
Xin Nie ◽  
Peng Zhang ◽  
Ning Lan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Liver Diseases ◽  
Meld Score ◽  
Hbv Infection ◽  
Expression Level ◽  
Control Group

Objective: Our study aims to detect the sensitivity of the new biomarker miR-212 existing in serum exosomes along with other hepatocellular carcinoma biomarkers such as AFP (alpha-fetoprotein), CA125 (carbohydrate antigen-ca125), and Hbx protein in the diagnosis of HBV-related liver diseases. We also aim to study the roles of these biomarkers in the progression of chronic hepatitis B and provide scientific data to show the clinical value of these biomarkers. Methods: We selected 200 patients with HBV-infection (58 cases of chronic hepatitis B, 47 cases of hepatocellular carcinoma, 30 cases of compensatory phase cirrhosis, and 65 cases of decompensatory phase cirrhosis), 31 patients with primary liver cancer without HBV infection, and 70 healthy individuals as the control group. The expression level of serum AFP and CA125 was detected with electrochemiluminescence immunoassay. The expression level of the Hbx protein was detected with ELISA. Meanwhile, the expression level of miR-212 in serum was analyzed with RT-qPCR. We collected patients’ clinical information following the Child-Pugh classification and MELD score criterion, and statistical analysis was made between the expression level of miR-212 and the collected clinical indexes. Lastly, we predicted the target genes of the miR-212 and its functions using bioinformatics methods such as cluster analysis and survival prediction. Results: Compared to the control group, the expression level of miR-212 in HBV infected patients was remarkably increased (P<0.05), especially between the HBV-infection Hepatocellular carcinoma group and the non-HBVinfection liver cancer group (P<0.05). The expression of miR-212 was increased in patients’ Child-Pugh classification, MELD score, and TNM staging. Moreover, the sensitivity and specificity of miR-212 were superior to AFP, CA125, and HBx protein. Conclusion: There is a linear relationship between disease progression and expression level of miR-212 in the serum of HBV infected patients. This demonstrates that miR-212 plays a significant role in liver diseases. miR-212 is expected to be a new biomarker used for the diagnosis and assessment of patients with HBV-infection-related liver diseases.

Sign in / Sign up

Export Citation Format

Share Document